Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Meletios-Athanasios Dimopoulos, ASH 2020 – Results from the Apollo Trial

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Dec 17th 2020

We caught up with Meletios-Athanasios Dimopoulos (National and Kapodistrian University of Athens School of Medicine, Athens, Greece) to discuss his ASH 2020 presentation on the use of daratumumab in the treatment of relapsed/refractory multiple myeloma (Clinical Trial Identification: NCT03180736). The abstract ‘412 Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)‘ (ABSTRACT NUMBER: 412) was presented at the Virtual 2020 ASH Congress, 2–10 December 2020.

Questions

  1. What are the major challenges and unmet needs when treating relapsed/refractory multiple myeloma? (0:08)
  2. What is the mode of action of daratumumab, and pomalidomide and dexamethasone, and what is the rationale behind the Apollo trial? (0:42)
  3. What were the aims and design of the Apollo trial? (3:00)
  4. What were the major safety and efficacy findings presented at this year’s ASH congress? (4:20)
  5. What will be the next steps in the clinical development of daratumumab, and how may it fit into treatment strategies? (6:08)

Speaker Disclosures: Meletios-Athanasios Dimopoulos discloses honoraria from participation in advisory boards from Amgen, Takeda, Beigene, Janssen and BMS.

Support: Interview and filming supported by Touch Medical Media Ltd.

Filmed in coverage of the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition 2020.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup